MUC1 and cancer: Moreover, targeting of TACAs could be relevant in combinatorial therapies, as they target glycans on the cell surface or in the tumour vasculature, thus, facilitating or enhancing the anti-cancer activity of other immunotherapeutics or drugs as it has been carried out with therapies targeting GD2 and MUC1 [91, 92].